Author

Kerstin Putzker

European Molecular Biology LaboratoryORCID 0000-0001-8375-5908Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Joe LewisiD· 2 shared Alina BatzillaiD· 1 shared Amirhossein SakhtemaniD· 1 shared Bernhard KüsteriD· 1 shared Firas HamoodiD· 1 shared Florian P BayeriD· 1 shared Hendrik SchürmanniD· 1 shared Jarno L. KiviojaiD· 1 shared

Activity by Year

2022-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Joe LewisORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response

Stefanie Höfer, Larissa Frasch, Sarah Brajkovic, Kerstin Putzker, Joe Lewis, Hendrik Schürmann, Valentina Leone, Amirhossein Sakhteman, Matthew The, Florian P Bayer, Julian Müller, Firas Hamood, Jens Thomas Siveke, Maximilian Reichert, Bernhard Küster

This study identifies ATR inhibitors as synergistic with gemcitabine in killing PDAC cells by blocking the DNA damage response pathway.

Molecular Systems Biology · Jan 21, 2025Peer-reviewedCancer Biology

Inferring tumor-specific cancer dependencies through integrating ex-vivo drug response assays and drug-protein profiling

Alina Batzilla, Junyan Lu, Jarno L. Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang K. Huber

The paper develops a method to infer tumor-specific molecular dependencies by integrating drug response assays with protein-drug affinity profiles, identifying known and novel dependencies in cancer types.

PLoS Computational Biology · Aug 22, 2022Peer-reviewedBioinformatics